nach oben

Erschienen in:

26.02.2015 | zertifizierte fortbildung

Von der Chemotherapie zur „targeted therapy“

Behandlung follikulärer Lymphome

verfasst von: Dr. med. Roswitha Forstpointner, Martin Dreyling

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das follikuläre Lymphom ist das häufigste indolente Lymphom. Es zeichnet sich durch einen langen, chronischen Verlauf aus. Eine Heilung ist bislang nicht möglich. Die Indikation zur Therapie muss individuell gestellt werden. Behandelt wird in fortgeschrittenen Stadien, in der Regel nur bei krankheitsassoziierten Symptomen, wie einer B-Symptomatik, einer hämatopoetischen Insuffizienz, bei Vorhandensein eines großen verdrängenden Lymphombulks oder bei einer raschen Krankheitsprogredienz.

Aisenberg AC. Malignant Lymphoma: Biology, natural history, and treatment. Erste Auflage. Philadelphia, London: Lea and Febiger; 1991.

McLaughlin P et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33.PubMed

Swerdlow S et al. WHO classification of tumours of haematopoetic and lymphoid tissues. Vierte Auflage. Genf: WHO; 2008.

Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827–34.CrossRefPubMed

Solal-Celigny P et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.CrossRefPubMed

Federico M et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62.CrossRefPubMed

Lowry L et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.CrossRefPubMed

Pugh TJ et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010;116(16):3843–51.CrossRefPubMed

Herfarth K, Schnaidt S. Early stage nodal follicular lymphoma using IF radiotherapy and Rituximab: Results of the MIR trial of the GLSG and ARO. Radiat Oncol (33rd ESTRO Meeting). 2014;111(Supl 1):Abstr 1098-PD.

10.

Colombat P et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101–6.CrossRefPubMed

11.

Friedberg JW et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–8.CrossRefPubMedCentralPubMed

12.

Ardeshna KM et al. An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstr 6.

13.

Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–35.CrossRefPubMed

14.

Schulz H et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706–14.CrossRefPubMed

15.

Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.CrossRefPubMed

16.

Federico M et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.CrossRefPubMed

17.

Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii76–82.CrossRef

18.

Vidal L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799–806.CrossRefPubMed

19.

Salles G et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.CrossRefPubMed

20.

Forstpointner R et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–8.CrossRefPubMed

21.

van Oers MH et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8.CrossRefPubMedCentralPubMed

22.

Taverna CJ et al. Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03. Blood (ASH Annual Meeting Abstracts). 2013;122(21):Abstr 508.

23.

Kahl BS et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096–102.CrossRefPubMed

24.

Morschhauser F et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. J Clin Oncol. 2013;31(16):1977–83.CrossRefPubMed

25.

Lopez-Guillermo A et al. A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. Blood (ASH Annual Meeting Abstracts). 2013;122(21):Abstr 369.

26.

Montoto S et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98(7):1014–21.CrossRefPubMedCentralPubMed

27.

Hiddemann W et al. Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma After Initial Immuno-Chemotherapy (R-CHOP) Or Chemotherapy Alone: Analysis Of 940 Patients Treated In Prospective Randomized Trials Of The German Low Grade Lymphoma Study Group (GLSG). Blood (ASH Annual Meeting Abstracts). 2013;122(21):Abstr 419.

28.

Sebban C et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614–20.CrossRefPubMed

29.

Czuczman MS et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698–704.CrossRefPubMed

30.

Salles G et al. Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients — Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL). Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstr 2868.

31.

Radford J et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137–43.CrossRefPubMed

32.

Viardot A et al. Eine offene Phase-2-Studie mit dem bi-spezifischen „T-cell engager’ (BiTE (R) ) Antikörper Blinatumomab bei Patienten mit rezidiviertem/therapierefraktärem diffusem großzelligen B-Zell-Lymphom. Oncol Res Treat (DGHO-Jahrestagung). 2014;37(suppl 5):Abstr 225.

33.

Bargou R et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–7.CrossRefPubMed

34.

Advani A et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–93.CrossRefPubMed

35.

Morschhauser F et al. Preliminary Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin (PoV) or Pinatuzumab Vedotin (PiV) Plus Rituximab (RTX) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2014;32(suppl);Abstr 8519.

36.

Coiffier B et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12(8):773–84.CrossRefPubMed

37.

Witzig TE et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27(32):5404–9.CrossRefPubMed

38.

Fowler NH et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311–8.CrossRefPubMed

39.

Pro B et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143(3):355–60.CrossRefPubMed

40.

Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.CrossRefPubMedCentralPubMed

41.

Flinn IW et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406–13.CrossRefPubMed

42.

Ponader S et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–9.CrossRefPubMed

43.

Advani RH et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.CrossRefPubMed

44.

Smith SM et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740–6.CrossRefPubMedCentralPubMed

45.

Hess G. Temsirolimus added to bendamustin and Rituximab (BERT): phase I results of a phase I/II-trial in patients with relapsed follicular lymphoma (FL) and mantle cell lymphoma (MCL). Hematol Oncol (12th International Conference on Malignant Lymphoma). 2013;31(Suppl 1):Abstr 149.

46.

Feuerlein K et al. First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma. 2009;50(3):325–34.CrossRefPubMed

Titel: Von der Chemotherapie zur „targeted therapy“
Behandlung follikulärer Lymphome
verfasst von: Dr. med. Roswitha Forstpointner
Martin Dreyling
Publikationsdatum: 26.02.2015
Verlag: Urban & Vogel
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 1/2015
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-015-0708-x

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Behandlung follikulärer Lymphome

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Neuer Prognosescore für Patienten mit Knochenmetastasen

Thorakale Radiatio bei SCLC positiv für das 2-Jahres-Überleben

Obinutuzumab auch bei älteren, komorbiden Patienten gut wirksam

Neuer Marker verbessert die Diagnose

Nierenzellkarzinom: Schlechte Prognose bei niedrigem Cholesterinspiegel

Neuer KI gegen Leukämie

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie